Autorità nazionali / Area COVID-19
Prodotti competitors / Area COVID-19
Ministero della Salute Canadese: EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
![Immagine News](/media/p55nhukr/cat-5.jpg?anchor=center&mode=crop&width=722&height=442)
EVUSHELD (tixagevimab and cilgavimab for injection) may not be effective against certain SARS-CoV-2 Omicron subvariants when used as a prophylaxis or treatment for COVID-19.
Healthcare professionals are advised to:
-
- Consider local epidemiology and individual exposure to circulating SARS-CoV-2 viral variants when making decisions regarding the use of EVUSHELD.
- Inform patients who receive EVUSHELD about the potential for a lack of effectiveness against certain SARS-CoV-2 viral variants. Instruct patients to seek medical advice if signs or symptoms of COVID-19 occur, persist or worsen.
- Refer to the EVUSHELD Canadian Product Monograph (CPM), in conjunction with the literature and local guidelines, for information regarding specific variants and antiviral resistance.The CPM for EVUSHELD has been updated with new information about the risk of prophylaxis or treatment failure due to antiviral resistance, including neutralization data on SARS-CoV-2 Omicron subvariants. For addictional infomation please visit https://recalls-rappels.canada.ca/en/alert-recall/evusheld-tixagevimab-and-cilgavimab-injection-risk-prophylaxis-or-treatment-failure-0
Grazie per il tuo feedback!